Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of Monoclonal Antibodies against SARS-CoV-2 N Protein
2.2. Antibody Pairing of Colloidal Gold Immunochromatography Strip
2.3. Evaluation of Sensitivity of Colloidal Gold Immunochromatography Strip
2.4. Preparation of a Test Paper for Identification of Omicron Mutant
2.5. Colloidal Gold Strip Cross-Reaction Detection
2.6. Anti-Interference Detection of Colloidal Gold Strip
2.7. The Minimum Detection Limit and Inclusiveness Detection of Colloidal Gold Dipstick
2.8. Stability Test of Colloidal Gold Dipstick
2.9. Study on Positive Judgment Value of Colloidal Gold Dipstick
3. Results
3.1. Screening Results of Anti-N Protein Monoclonal Antibodies
3.2. Screening Results of Colloidal Gold Dipstick
3.3. Sensitivity of Colloidal Gold Test Paper for Detecting α, β, δ, and ο Mutants
3.4. Single-Card Double-T Strip Test for Omicron Mutant Strain
3.5. Colloidal Gold Dipstick Cross-Reaction Verification
3.6. Anti-Interference Test Results of Colloidal Gold Dipstick
3.7. Verification of the Minimum Detection Limit and Inclusiveness of Colloidal Gold Dipstick
3.8. Stability Verification of the Test Strip for SARS-CoV-2 Antigen Detection
3.9. Study on the Positive Value of Colloidal Gold Strip
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- SeyedAlinaghi, S.; Mirzapour, P.; Dadras, O.; Pashaei, Z.; Karimi, A.; MohsseniPour, M.; Soleymanzadeh, M.; Barzegary, A.; Afsahi, A.M.; Vahedi, F.; et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: A systematic review. Eur. J. Med. Res. 2021, 26, 51. [Google Scholar] [CrossRef] [PubMed]
- Liu, Q.; Qin, C.; Liu, M.; Liu, J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis. Infect. Dis. Poverty 2021, 10, 132. [Google Scholar] [CrossRef] [PubMed]
- Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J.C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.H.; Michailidis, E.; et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 2020, 9, e61312. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.; Liu, L.; Kou, G.; Zheng, Y.; Ding, Y.; Ni, W.; Wang, Q.; Tan, L.; Wu, W.; Tang, S.; et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. 2020, 58, e00461–20. [Google Scholar] [CrossRef] [Green Version]
- Kadam, S.B.; Sukhramani, G.S.; Bishnoi, P.; Pable, A.A.; Barvkar, V.T. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J. Basic Microbiol. 2021, 61, 180–202. [Google Scholar] [CrossRef]
- Wang, P.; Nair, M.S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P.D.; et al. Antibody resistance to SARS-CoV-2 infection B.1.351 and B.1.1.7. Nature 2011, 593, 130–135. [Google Scholar] [CrossRef]
- Shen, M.; Zhou, Y.; Ye, J.; Abdullah Al-Maskri, A.A.; Kang, Y.; Zeng, S.; Cai, S. Recent advances and perspectives of nucleic acid detection for coronavirus. J. Pharm. Anal. 2020, 10, 97–101. [Google Scholar] [CrossRef]
- Diao, B.; Wen, K.; Chen, J.; Liu, Y.; Yuan, Z.; Han, C.; Chen, J.; Pan, Y.; Chen, L.; Dan, Y.; et al. Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. medRxiv 2020. [Google Scholar] [CrossRef]
- Ascoli, C.A. Could mutations of SARS-CoV-2 suppress diagnostic detection. Nat. Biotechnol. 2021, 39, 274–275. [Google Scholar] [CrossRef]
- Fan, C.; Ye, X.; Ku, Z.; Kong, L.; Liu, Q.; Xu, C.; Cong, Y.; Huang, Z. Beta-propiolactone inactivation of coxsackievirus A16 induces structural alteration and surface modification of viral capsids. J. Virol. 2017, 91, e00038-17. [Google Scholar] [CrossRef]
- Dinnes, J.; Deeks, J.; Berhane, S.; Taylor, M.; Adriano, A.; Davenport, C.; Dittrich, S.; Emperador, D.; Takwoingi, Y.; Cunningham, J.; et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2021, 3, CD013705. [Google Scholar]
- Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; et al. Effects of α-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005, 46, 857–868. [Google Scholar] [CrossRef] [Green Version]
- Thakur, N.; Conceicao, C.; Isaacs, A.; Human, S.; Modhiran, N.; McLean, R.K.; Pedrera, M.; Tan, T.K.; Rijal, P.; Townsend, A.; et al. Micro-fusion inhibition tests: Quantifyingantibody neutralization of virus-mediated cell-cell fusion. J. Gen. Virol. 2021, 102, 105–109. [Google Scholar] [CrossRef]
- Zavrtanik, U.; Lukan, J.; Loris, R.; Lah, J.; Hadži, S. Structural basis of epitope recognition by heavy-chain camelid antibodies. J. Mol. Biol. 2018, 430, 4369–4386. [Google Scholar] [CrossRef]
- Vuorela, A.; Freitag, T.L.; Leskinen, K.; Pessa, H.; Härkönen, T.; Stracenski, I.; Kirjavainen, T.; Olsen, P.; Saarenpää-Heikkilä, O.; Ilonen, J.; et al. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat. Commun. 2021, 12, 2283. [Google Scholar] [CrossRef]
- Goncalves, J.; Santos, M.; Acurcio, R.; Iria, I.; Gouveia, L.; Matos Brito, P.; Catarina Cunha-Santos, A.; Barbas, A.; Galvão, J.; Barbosa, I.; et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment. Pharmacol. Ther. 2018, 48, 507–522. [Google Scholar] [CrossRef]
- Song, S.; Suryoprabowo, S.; Liu, L.; Kuang, H.; Xu, L.; Ma, W. Development of monoclonal antibody-based colloidal gold immunochromatographic assay for analysis of halofuginone in milk. Food Agric. Immunol. 2019, 30, 112–122. [Google Scholar] [CrossRef] [Green Version]
- Wu, Y.; Wu, M.; Liu, C.; Tian, Y.; Fang, S.; Yang, H.; Li, B.; Liu, Q. Colloidal gold immunochromatographic test strips for broad-spectrum detection of Salmonella. Food Control 2021, 126, 108052. [Google Scholar] [CrossRef]
- Huang, C.; Wen, T.; Shi, F.J.; Zeng, X.Y.; Jiao, Y.J. Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay. ACS Omega 2020, 5, 12550–12556. [Google Scholar] [CrossRef]
- Sun, C.; Kang, Y.F.; Liu, Y.T.; Kong, X.W.; Xu, H.Q.; Xiong, D.; Xie, C.; Liu, Y.H.; Peng, S.; Feng, G.K.; et al. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Signal Transduct. Target. Ther. 2022, 7, 42. [Google Scholar] [CrossRef]
- Lamb, L.E.; Bartolone, S.N.; Ward, E.; Chancellor, M.B. Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. PLoS ONE 2020, 15, e0234682. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.-R.; Zhou, Z.-J.; Cheng, X.-L.; Yang, S.; Li, Q.; Luo, M.; Shi, Y.-H.; Li, C.-S.; Li, T.-J. Establishment of sample panel for detection of SARS-CoV-2 antigen and its application in development and quality evaluation of colllidal gold test cassettes. Chin. J. Biol. 2022, 35, 293–298+303. [Google Scholar] [CrossRef]
- Guidelines for the Registration and Review of Novel Coronavirus(2019-nCoV) Antigen Detection Reagents; Medical Device Technical Review Center, China National Medical Products Administration: Beijing, China, 2020.
- She, Y.M.; Cheng, K.; Farnsworth, A.; Li, X.; Cyr, T.D. Surface modifications of influenza proteins upon virus inactivation by β-prop. Proteomics 2013, 13, 3537–3547. [Google Scholar] [CrossRef] [PubMed]
Interfering Substance | Concentration | Interfering Substance | Concentration | Interfering Substance | Concentration |
---|---|---|---|---|---|
Mucin | 0.1% | Oxymetazoline | 200 µg/mL | Levofloxacin | 6.27 µg/mL |
0.05% | 100 µg/mL | 3.14 µg/mL | |||
Alpha interferon | 1.57 mg/mL | Histamine hydrochloride | 200 µg/mL | Azithromycin | 5.23 µg/mL |
3.14 mg/mL | 100 µg/mL | 2.62 µg/mL | |||
Zanamivir | 142 ng/mL | Phenylephrine | 20 µg/mL | Ceftriaxone | 200 µg/mL |
71 ng/mL | 10 µg/mL | 100 µg/mL | |||
Ribavirin | 4 mg/mL | Beclomethasone Dipropionate | 0.3 µg/mL | Meropenem | 112 µg/mL |
2 mg/mL | 0.15 µg/mL | 56 µg/mL | |||
Oseltamivir | 1.275 mg/mL | Dexamethasone | 0.3 µg/mL | Tobramycin | 4 µg/mL |
0.638 mg/mL | 0.15 µg/mL | 2 µg/mL | |||
Palmer peramivir | 23 µg/mL | Flunisolide | 0.075 µg/mL | Sodium chloride (with preservatives) | 0.85% |
11.5 µg/mL | 0.3 µg/mL | 0.43% | |||
Lopinavir | 13.2 µg/mL | Triamcinolone acetonide | 0.5 µg/mL | Mometasone | 200 µg/mL |
6.6 µg/mL | 0.25 µg/mL | 100 µg/mL | |||
Ritonavir | 53 µg/mL | Budesonide | 0.275 µg/mL | Fluticasone | 0.3 ng/mL |
26.5 µg/mL | 0.138 µg/mL | 0.15 ng/mL | |||
Arbidol | 658.5 ng/mL | ||||
329.25 ng/mL |
Dilution | Ab1 | Ab2 | Ab3 | Ab4 | Ab5 | Ab6 | Ab7 | |
---|---|---|---|---|---|---|---|---|
1 | 1:2000 | 2.9273 | 2.8347 | 2.9312 | 2.8819 | 2.8361 | 2.8177 | 2.8388 |
2 | 1:4000 | 2.8751 | 2.8585 | 2.8830 | 2.8012 | 2.8494 | 2.7350 | 2.8617 |
3 | 1:8000 | 2.7272 | 2.8057 | 2.9817 | 2.8998 | 2.8072 | 2.8722 | 2.8006 |
4 | 1:16,000 | 2.5464 | 2.0330 | 2.7113 | 2.6177 | 2.2153 | 2.5728 | 2.2679 |
5 | 1:32,000 | 2.2422 | 1.6490 | 2.4771 | 2.4834 | 1.8094 | 2.4213 | 1.8755 |
6 | 1:64,000 | 1.8523 | 1.2831 | 1.7938 | 1.7334 | 1.2693 | 1.7220 | 1.2779 |
7 | 1:128,000 | 1.3884 | 0.7246 | 1.2932 | 1.2618 | 0.7387 | 1.0763 | 0.7530 |
8 | 1:256,000 | 1.0423 | 0.3942 | 0.8201 | 0.8069 | 0.3968 | 0.7441 | 0.4063 |
9 | 1:512,000 | 0.8228 | 0.1650 | 0.4624 | 0.4455 | 0.1683 | 0.3612 | 0.1819 |
10 | 1:1,024,000 | 0.6196 | 0.0826 | 0.2424 | 0.2375 | 0.0821 | 0.2176 | 0.0929 |
11 | Blank | 0.0702 | 0.0589 | 0.0604 | 0.0534 | 0.0611 | 0.0442 | 0.0608 |
12 | Blank | 0.0684 | 0.0518 | 0.0512 | 0.0510 | 0.0443 | 0.0462 | 0.0425 |
Dilution Ratio | 102 | 103 | 104 | CON | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pairs of Antibody | α | β | δ | ο | α | β | δ | ο | α | β | δ | ο | ||
1 | +++ | +++ | +++ | + | ++ | ++ | ++ | - | - | - | - | - | - | |
2 | +++ | +++ | +++ | - | ++ | ++ | ++ | - | + | + | - | - | - | |
3 | +++ | +++ | +++ | - | ++ | ++ | ++ | - | + | + | - | - | - | |
4 | +++ | +++ | +++ | +++ | ++ | ++ | ++ | ++ | + | + | + | + | - | |
5 | ++ | ++ | ++ | - | + | + | + | - | + | + | + | - | - | |
6 | +++ | +++ | +++ | - | ++ | ++ | ++ | - | + | + | + | - | - |
Dilution | The CT Value of the TEXAS RED Channel (ORF1ab) | The CT Value of the FAM Channel (N) | Results |
---|---|---|---|
1:10 | 16.98 | 16.87 | positive |
1:102 | 19.47 | 19.71 | positive |
1:103 | 25.43 | 25.77 | positive |
1:104 | 26.31 | 26.50 | positive |
1:105 | 29.85 | 29.92 | positive |
1:106 | 33.16 | 33.56 | positive |
1:107 | 35.11 | 35.66 | positive |
1:108 | 37.56 | 37.24 | negative |
1:109 | 37.78 | 37.98 | negative |
1:1010 | 37.59 | 37.73 | negative |
Sample | Detection Result | Sample | Detection Result | ||||
---|---|---|---|---|---|---|---|
1 | 2 | 3 | 1 | 2 | 3 | ||
Coronavirus HKU1 | - | - | - | Adenovirus type 4 | - | - | - |
Coronavirus OC43 | - | - | - | Adenovirus type 5 | - | - | - |
Coronavirus NL63 | - | - | - | Adenovirus type 7 | - | - | - |
Coronavirus 229E | - | - | - | Adenovirus type 55 | - | - | - |
SARS | - | - | - | Enterovirus group A | - | - | - |
MERS | - | - | - | Enterovirus group B | - | - | - |
Novel influenza A (H1N1) virus (2009) | - | - | - | Enterovirus group C | - | - | - |
Seasonal H1N1 influenza virus | - | - | - | Enterovirus group D | - | - | - |
H3N2 | - | - | - | Epstein-barr virus | - | - | - |
H5N1 | - | - | - | Measles virus | - | - | - |
H7N9 | - | - | - | Human cytomegalovirus | - | - | - |
Influenza B Yamagata | - | - | - | Rotavirus | - | - | - |
Influenza B Victoria | - | - | - | Norovirus | - | - | - |
Parainfluenza virus type I | - | - | - | Mumps virus | - | - | - |
Parainfluenza virus type II | - | - | - | Varicella-zoster virus | - | - | - |
Parainfluenza virus type III | - | - | - | Human metapneumovirus | - | - | - |
Respiratory syncytial virus type A | - | - | - | Mycoplasma pneumoniae | - | - | - |
Respiratory syncytial virus type B | - | - | - | Chlamydia pneumoniae | - | - | - |
Human rhinovirus group A | - | - | - | Haemophilus influenzae | - | - | - |
Human rhinovirus group B | - | - | - | Staphylococcus aureus | - | - | - |
Human rhinovirus group C | - | - | - | Streptococcus pneumoniae | - | - | - |
Adenovirus type 1 | - | - | - | Klebsiella pneumoniae | - | - | - |
Adenovirus type 2 | - | - | - | Mycobacterium tuberculosis | - | - | - |
Adenovirus type 3 | - | - | - | Candida albicans | - | - | - |
Sample | Concentration | Detection Result | Sample | Concentration | Detection Result | ||||
---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 1 | 2 | 3 | ||||
Mucin | 0.1% | + | + | + | Dexamethasone | 0.3 ng/mL | + | + | + |
0.05% | + | + | + | 0.15 ng/mL | + | + | + | ||
Alpha interferon | 1.57 mg/mL | + | + | + | Flunisolide | 0.075 ng/mL | + | + | + |
3.14 mg/mL | + | + | + | 0.3 ng/mL | + | + | + | ||
Zanamivir | 142 ng/mL | + | + | + | Triamcinolone acetonide | 0.5 ng/mL | + | + | + |
71 ng/mL | + | + | + | 0.25 ng/mL | + | + | + | ||
Ribavirin | 4 mg/mL | + | + | + | Budesonide | 0.275 µg/L | + | + | + |
2 mg/mL | + | + | + | 0.138 µg/L | + | + | + | ||
Oseltamivir | 1.275 mg/mL | + | + | + | Levofloxacin | 6.27 µg/mL | + | + | + |
0.638 mg/mL | + | + | + | 3.14 µg/mL | + | + | + | ||
Palmer peramivir | 23 µg/mL | + | + | + | Azithromycin | 5.23 µg/mL | + | + | + |
11.5 µg/mL | + | + | + | 2.62 µg/mL | + | + | + | ||
Lopinavir | 13.2 µg/mL | + | + | + | Ceftriaxone | 200 µg/mL | + | + | + |
6.6 µg/mL | + | + | + | 100 µg/mL | + | + | + | ||
Ritonavir | 53 µg/mL | + | + | + | Meropenem | 112 µg/mL | + | + | + |
26.5 µg/mL | + | + | + | 56 µg/mL | + | + | + | ||
Arbidol | 658.5 ng/mL | + | + | + | Tobramycin | 4 µg/mL | + | + | + |
329.25 ng/mL | + | + | + | 2 µg/mL | + | + | + | ||
Oxymetazoline | 200 µg/mL | + | + | + | Sodium chloride (with preservatives) | 0.85% | + | + | + |
100 µg/mL | + | + | + | 0.43% | + | + | + | ||
Histamine hydrochloride | 200 µg/mL | + | + | + | Mometasone | 200 µg/mL | + | + | + |
100 µg/mL | + | + | + | 100 µg/mL | + | + | + | ||
Phenylephrine | 20 µg/mL | + | + | + | Fluticasone | 0.3 µg/mL | + | + | + |
10 µg/mL | + | + | + | 0.15 µg/mL | + | + | + | ||
Beclometasone Dipropionate | 0.3 ng/mL | + | + | + | |||||
0.15 ng/mL | + | + | + |
Strain Types | Dilution/ TCID50/mL | Positive Numbers | Negative Numbers | Positive Rates | Results |
---|---|---|---|---|---|
Original | 125 | 400 | 0 | 100% | Positive |
62.5 | 400 | 0 | 100% | Positive | |
31.25 | 20 | 380 | 5% | Negative | |
β | 125 | 400 | 0 | 100% | Positive |
62.5 | 400 | 0 | 100% | Positive | |
31.25 | 25 | 375 | 6.25% | Negative | |
δ | 125 | 400 | 0 | 100% | Positive |
62.5 | 400 | 0 | 100% | Positive | |
31.25 | 12 | 388 | 0.25% | Negative | |
Omicron | 125 | 400 | 0 | 100% | Positive |
62.5 | 400 | 0 | 100% | Positive | |
31.25 | 392 | 8 | 98% | Positive |
Sample | Antigen Test Result | Nucleic Acid Test Result | ORFlab | N | Sample | Antigen Test Result | Nucleic Acid Test Result | ORFlab | N | Sample | Antigen Test Result | Nucleic Acid Test Result | ORFlab | N |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | + | + | 23.25 | 21.55 | 34 | + | + | 16.79 | 16.29 | 67 | + | + | 18.27 | 17.92 |
2 | + | + | 22.23 | 21.71 | 35 | + | + | 16.57 | 15.91 | 68 | + | + | 22.97 | 21.81 |
3 | + | + | 16.08 | 14.38 | 36 | + | + | 19.21 | 17.49 | 69 | + | + | 23.74 | 22.81 |
4 | + | + | 20.2 | 19.49 | 37 | + | + | 17.7 | 17.5 | 70 | + | + | 20.08 | 19.04 |
5 | + | + | 17.65 | 15.93 | 38 | + | + | 18.94 | 18.13 | 71 | + | + | 13.07 | 11.63 |
6 | + | + | 19.58 | 18.04 | 39 | - | + | 21.67 | 20.24 | 72 | + | + | 18.25 | 17.2 |
7 | - | + | 33.61 | 33.09 | 40 | + | + | 21.26 | 2.06 | 73 | + | + | 21.14 | 20.62 |
8 | + | + | 19.49 | 17.4 | 41 | + | + | 16.87 | 14.77 | 74 | + | + | 29.56 | 29.16 |
9 | + | + | 14.11 | 12.95 | 42 | + | + | 15.93 | 13.8 | 75 | + | + | 15.51 | 14.3 |
10 | + | + | 21.96 | 20.77 | 43 | + | + | 14.33 | 13.12 | 76 | + | + | 20.84 | 19.47 |
11 | + | + | 22.41 | 20.76 | 44 | + | + | 25.17 | 24.98 | 77 | + | + | 19.23 | 18.09 |
12 | + | + | 16.55 | 15.68 | 45 | + | + | 14.25 | 13.36 | 78 | + | + | 15.52 | 14.23 |
13 | - | + | 21.03 | 20.22 | 46 | + | + | 21.59 | 19.99 | 79 | + | + | 18.28 | 16.43 |
14 | + | + | 18.22 | 17.04 | 47 | + | + | 20.92 | 20.4 | 80 | - | + | 30.47 | 29.89 |
15 | + | + | 23.12 | 21.25 | 48 | + | + | 17.92 | 15.85 | 81 | + | + | 32.65 | 32.18 |
16 | + | + | 21.27 | 21.41 | 49 | + | + | 24.66 | 24.11 | 82 | + | + | 30.12 | 28.47 |
17 | + | + | 35.21 | 34.48 | 50 | - | + | 26.45 | 26.36 | 83 | - | + | - | 39.3 |
18 | + | + | 21.11 | 20.86 | 51 | + | + | 19.14 | 17.88 | 84 | + | + | 30.83 | 28.87 |
19 | + | + | 21.47 | 21.05 | 52 | + | + | 19.19 | 17.52 | 85 | + | + | 33.33 | 32.79 |
20 | - | + | 19.15 | 17.38 | 53 | + | + | 20.94 | 19.14 | 86 | + | + | 36.2 | 35.17 |
21 | + | + | 13.83 | 11.99 | 54 | + | + | 17.35 | 15.68 | 87 | + | + | 32.09 | 30.84 |
22 | + | + | 15.02 | 12.54 | 55 | + | + | 18.9 | 18.14 | 88 | + | + | 31.17 | 29.61 |
23 | + | + | 14.4 | 12.77 | 56 | + | + | 7.67 | 15.18 | 89 | + | + | 37.47 | 38.09 |
24 | - | + | 24.87 | 23.92 | 57 | + | + | 18.2 | 17.35 | 90 | + | + | 23.77 | 22.38 |
25 | + | + | 20.99 | 20.02 | 58 | + | + | 18.5 | 17.79 | 91 | + | + | 29.03 | 27.83 |
26 | - | + | 35.7 | 35.15 | 59 | + | + | 26.35 | 26.03 | 92 | + | + | 30.87 | 29.09 |
27 | - | + | 17.08 | 15.26 | 60 | + | + | 25.42 | 23.58 | 93 | + | + | 27.79 | 24.8 |
28 | + | + | 18.4 | 17.98 | 61 | + | + | 19.16 | 17.89 | 94 | + | + | 30.71 | 29.54 |
29 | + | + | 16.97 | 16.27 | 62 | + | + | 23.89 | 23.42 | 95 | + | + | 16.26 | 13.19 |
30 | + | + | 23.88 | 23.07 | 63 | + | + | 21.7 | 20.58 | 96 | + | + | 32.24 | 29.38 |
31 | + | + | 26.13 | 26.17 | 64 | + | + | 15.85 | 14.79 | 97 | + | + | 32.78 | 30.95 |
32 | + | + | 18.34 | 17.94 | 65 | + | + | 19.16 | 17.89 | 98 | + | + | 33.79 | 31.44 |
33 | + | + | 18.01 | 17.16 | 66 | + | + | 23.74 | 22.65 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, J.; Shi, J.; Zhou, Z.; Yang, B.; Cao, J.; Cao, Z.; Zeng, Q.; Hu, Z.; Yang, X. Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2. Vaccines 2023, 11, 303. https://doi.org/10.3390/vaccines11020303
Li J, Shi J, Zhou Z, Yang B, Cao J, Cao Z, Zeng Q, Hu Z, Yang X. Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2. Vaccines. 2023; 11(2):303. https://doi.org/10.3390/vaccines11020303
Chicago/Turabian StyleLi, Jiaji, Jinrong Shi, Zhijun Zhou, Bo Yang, Jiamin Cao, Zhongsen Cao, Qiang Zeng, Zheng Hu, and Xiaoming Yang. 2023. "Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2" Vaccines 11, no. 2: 303. https://doi.org/10.3390/vaccines11020303
APA StyleLi, J., Shi, J., Zhou, Z., Yang, B., Cao, J., Cao, Z., Zeng, Q., Hu, Z., & Yang, X. (2023). Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2. Vaccines, 11(2), 303. https://doi.org/10.3390/vaccines11020303